drugset / Trial / NCT01327300

Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)

NCT01327300

Phase 2 Completed 7 enrolled University of Florida
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to find whether treating patients with diarrhea predominant Irritable Bowel Syndrome (IBS) with an anti-inflammatory drug called Mesalamine will help improve their symptoms of diarrhea, bloating and abdominal pain.

Timeline

Start
2010-03
Primary completion
2012-03
Completion
2012-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mesalamine Small molecule 1.5 g Oral